

Genentech How we Continue to Innovate

Christine Buesnel March 21, 2017



Disclaimer

• This presentation reflects my thinking only

• There are many vendors, including Teradata who are pivotal to our innovation.

• I am not a scientist.



Genentech's Beginning... 2 stories





Napo, by an image of a molecular model of Avastin, which was developed based on his earlier discovery of VEGF.




(Roche)

Genentech (Roche) now

• 88,509 employees

Global spend on R&D Roche #1 among Healthcare companies






Competitors accelerating their R&D programs

Regulators support alternative approaches



- minimal data set
- Accelerated entry by >6 months

Keytruda: Adaptive, phaseless R&D





- Approval in just over 3 years after • entering Keynote-001
- Leapfrogging in 1L lung combo ٠



Periods of exclusivity shortening

Important to be early to market & compete effectively





Six RED molecules in initial JEWEL pilot Potential launch acceleration up to 8 quarters

We are looking for ways to replicate the innovative environment.

Create an innovation function accountable for thinking and driving innovations.

PD Strategic Innovation is a cross-disciplinary team that accelerates the transformation of drug development to meet future needs of patients.



Evolve a new Data Ecology with an individual patient in mind Patient Centered Development

Create New Trial Models to meet the evidence needs of the future

We are looking for ways to replicate the innovative environment.

Invest in an infrastructure where the smart people can innovate and create.

- Technology
 - GLIDE
 - EDIS
- People
 - Medical Data Hub
 - Real World Data
- Process
 - RAAN
 - Connected culture





Key Messages

 Innovation occurs when the environment is right

Seems easier in a small company than a larger one

 Need to be overt and try multiple approaches to enable innovation



Doing now what patients need next